Quantity | = | Concentration | x | Volume | x | Molecular Weight |
---|---|---|---|---|---|---|
= | x | x |
1) Click the Molarity Calculation Cart® button.
2) Specify the Concentration and Volume of your desired Molarity.
3) Click Calculate.
4) Your desired Quantity will be calculated and will be put under Quantity: (only for mg)
5) Click Add to Cart and then Proceed to checkout to complete the order. You will receive the quantity as you ordered as solvent-free form.
Alert: If you want to make a solution with a solvent (such DMSO), please add instructions in the notes section (such as 10 nM/1 mL in DMSO) and we will pack and deliver the product as a solution (such as 10 nM solution in 1 mL DMSO). If the product cannot be dissolved in DMSO or you would like to specify your own preferred solvent, please add detailed instructions in the notes section. All solutions must be shipped with an ice bag, costing an additional fee of $20 for S&H.
AOB12591
CAS: 2170137-61-6
Chemical Name: 2-((6-(4-Aminopiperidin-1-yl)-3,5-dicyano-4-ethylpyridin-2-yl)thio)-2-phenylacetamide
Warning: Last items in stock!
Availability date:
Quantity | mg | Unit Price ($/mg or $/Unit) | Final Price |
---|---|---|---|
1 | 100 | $9.45 | Total: $945.00 |
1 | 50 | $10.92 | Total: $546.00 |
1 | 25 | $12.81 | Total: $320.25 |
1 | 10 | $15.12 | Total: $151.20 |
1 | 5 | $17.85 | Total: $89.25 |
Molecular Formula | C22H24N6OS |
Molecular Weight | 420.54 |
CAS Numbers | 2170137-61-6 |
Storage Condition | 0°C (short term), -20°C (long term), desiccated |
Purity | 99% (HPLC) |
Synonym | GSK-3685032, GSK 3685032 |
IUPAC/Chemical Name | 2-((6-(4-Aminopiperidin-1-yl)-3,5-dicyano-4-ethylpyridin-2-yl)thio)-2-phenylacetamide |
References | 1) Melissa B. Pappalardi et al., Discovery of a first-in-class reversible DNMT1-selective inhibitor with improved tolerability and efficacy in acute myeloid leukemia, Nature Cancer volume 2, pages1002–1017 (2021) |
First-in-class potent, non-nucleoside, reversible, DNMT1-selective inhibitor (IC50: 0.17 µM), exerting robust DNA hypomethylation and gene activation, potently inhibiting growth of cancer cell lines, displaying improved tolerability and greater DNA hypomethylation than decitabine (DAC), translating into superior antitumour activity in models of AML.